Your session is about to expire
← Back to Search
Pegylated Interferon-alpha2a + Panobinostat for HIV/AIDS (ACTIVATE Trial)
ACTIVATE Trial Summary
This trial will study whether a combination of two drugs can reduce the amount of HIV-infected cells in people who are already taking antiretroviral drugs.
- HIV/AIDS
ACTIVATE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowACTIVATE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 3 trial • 41 Patients • NCT01034163ACTIVATE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You agree to use birth control for 90 days after finishing the treatment.If you are a male, you need to agree to use a condom during sex while taking panobinostat and for 80 hours after stopping treatment.
- Group 1: Arm B
- Group 2: Arm C
- Group 3: Arm A
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any precedents for the usage of Panobinostat in clinical research?
"Currently, 25 trials are in progress exploring Panobinostat. Of these studies, two have reached Phase 3 status. The majority of research sites dedicated to investigating this medication are located in Barcelona and New york City; however, 411 clinical trial centres across the globe are participating."
Does this research project currently have openings for participants?
"This clinical trial has ended its recruitment phase. It was initially published on May 1st 2016 and last edited on July 6th 2022. For those seeking other trials, there are currently 634 studies recruiting HIV-infected patients and 25 Panobinostat trials searching for participants."
To what end is Panobinostat normally prescribed?
"Panobinostat can potentially treat multiple chronic and compensated liver diseases, including hepatitis b and C."
How many participants are partaking in this medical research?
"This research endeavour is no longer seeking participants, having been initially posted on May 1st 2016 and last updated on July 6th 2022. If you are in search of other studies, there are currently 634 clinical trials actively recruiting individuals with HIV infections and 25 separate initiatives utilizing Panobinostat that require volunteers."
Does your study accept elderly participants?
"This experiment necessitates that qualified participants fall between the ages of 18-65. Separate trials are available for those younger than 18, and those older than 65; 153 in total for minors and 485 for seniors."
Is it possible for me to participate in this research endeavor?
"To be admitted to this trial, applicants must possess HIV infections and meet the age range of 18-65. In total, 34 participants are being accepted for the study."
Share this study with friends
Copy Link
Messenger